Roxithromycin
Roxid · Rulid · Roxithromycin (Roxl-150) · Roxithromycin Solution, 100ppm · Brilid · Overal · RU 965 · Surlid
Identifiers & Physical Properties
| CAS No. | 80214-83-1 |
|---|---|
| Molecular formula | C41H76N2O15 |
| Average molar mass | 837 g/mol |
| Monoisotopic mass | 836.52456972 g/mol |
| SMILES | CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)/C(=N\OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O |
| InChIKey | RXZBMPWDPOLZGW-XMRMVWPWSA-N |
| PubChem CID | 6915744 |
| ChEMBL | CHEMBL1214185 |
| ChEBI | CHEBI:48844 |
| EC No. | 617-007-5 |
Chemical & Physical Properties
| XLogP | 3.1 |
|---|---|
| Topological polar surface area | 217 |
| Hydrogen bond donors | 5 |
| Hydrogen bond acceptors | 17 |
| Rotatable bonds | 13 |
| Heavy atoms | 58 |
| Formal charge | 0 |
| Complexity | 1,310 |
| Drugs | Pharmaceuticals -> AntibioticsPharmaceuticals -> Listed in ZINC15 |
| LogP (partition coefficient) | 3.46 |
| Human Drugs | Breast FeedingLactationAnti-Bacterial AgentsAnti-Infective AgentsMacrolides |
| Dissociation Constants | 9.27 |
| Collision Cross Section | 285.66 Ų [M+Na]+ |
| Melting point | 111-118C |
| Boiling point | 864.7±75.0 °C(Predicted) |
| alpha | D25 -77.5 ±2° (c = 0.45 in chloroform) |
| Density | 1.25±0.1 g/cm3(Predicted) |
| Flash point | >110°(230°F) |
| Storage conditions | Sealed in dry,2-8°C |
| Solubility | chloroform: soluble10mg/mLSoluble in water to 18µ |
| pKa (acidity coefficient) | pKa 9.27±0.01(H2O t = 25.0 I = 0.15 (KCl)) (Uncertain) |
| Physical state | powder |
| Color | White to off-white |
| Merck | 14,8276 |
| Major applications | pharmaceutical (small molecule) |
| InChIKey | RXZBMPWDPOLZGW-HEWSMUCTSA-N |
| SMILES | CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC3OC(C)CC(C3O)N(C)C)C(C)(O)CC(C)C(=N/OCOCCOC)\C(C)C(O)C1(C)O |
| CAS DataBase Reference | 80214-83-1 |
| FDA UNII | 21KOF230FA |
| ATC code | J01FA06 |
| EPA Substance Registry System | Erythromycin, 9-[O-[(2-methoxyethoxy)methyl]oxime], (9E)- (80214-83-1) |
| UNSPSC Code | 41116107 |
| NACRES | NA.24 |
| GHS pictogram | GHS07 |
| Signal word | Warning |
| GHS hazard statements | H302 |
| GHS precautionary statements | P264-P270-P301+P312-P501 |
| Hazard symbols | Xn |
| Risk statements (R) | 22 |
| Safety statements (S) | 26-24/25 |
| Water hazard class (WGK) | 3 |
| RTECS number | KF4990000 |
| Customs code | 29415000 |
| Storage class | 11 - Combustible Solids |
| Hazard class | Acute Tox. 4 Oral |
Safety & Regulations
| GHS classification | WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 67 reports by companies from 2 notifications to the ECHA C&L Inventory.DangerH302: Harmful if swallowed [Warning Acute toxicity, oral] |
|---|---|
| Regulatory information | Roxithromycin: Does not have an individual approval but may be used under an appropriate group standard |
| Hazard Classes and Categories | Acute Tox. 4 (100%)Acute toxicity (Oral) - Category 4 |
| Drug Induced Liver Injury | Drug-Induced Liver Injury Severity and Toxicity (DILIst)ROXITHROMYCINDILI PositiveDOI:10.1016/j.drudis.2019.09.022 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
| Water hazard class (WGK) | 3 |
| RTECS number | KF4990000 |
| Customs code | 29415000 |
| Risk statements (R) | 22 |
| Signal word | Warning |
| GHS pictogram | GHS07 |
| Hazard symbols | Xn |
| Safety statements (S) | 26-24/25 |
| Storage class | 11 - Combustible Solids |
| GHS hazard statements | H302 |
| Hazard class | Acute Tox. 4 Oral |
| GHS precautionary statements | P264-P270-P301+P312-P501 |
Applications & Uses
Uses
1. It belongs to macrolide antibiotics, being a kind of erythromycin derivative with the antibacterial spectrum being similar as erythromycin but having a 6 times stronger effect on erythromycin with high bioavailability. It is used for the treatment of respiratory tract infection, such as pneumonia, acute bronchitis, acute infection of chronic bronchitis, atypical pneumonia, and genitourinary system infection, skin and soft tissue infections, having good therapeutic effect and tolerance with smaller adverse reactions than erythromycin. 2. As the new generation of macrolide antibiotics; 3. The product belongs to a new generation of macrolide antibiotics, mainly used for Gram-positive bacteria, anaerobes, chlamydia and mycoplasma. Its antibacterial activity in vitro is similar as erythromycin with its in vivo effect being 1-4 times stronger than erythromycin. Pharmacological effects and indications 1, it has strong bactericidal effect on Gram-negative bacteria and some Gram-negative bacteria (meningococcus, Neisseria gonorrhoeae, influenza bacilli, pertussis, Brucella) and spirochetes, Mycoplasma pneumoniae and Rickettsia. Legionella is sensitive to it; its effect against mycoplasma and chlamydia is further enhanced. 4. 2, antibacterial mechanism: it can bind to the bacterial ribosome 50S subunit, through blocking the peptidyl transfer and MRNA displacement, further inhibiting the protein synthesis. 3, this product has excellent oral absorption and quick efficacy with stronger bioavailability and plasma concentrations than erythromycin. According to reports, oral administration of 150 mg can lead to a peak plasma concentration of up to 6.6~7.9 ug/ml while the value for erythromycin under the same conditions is only 0.2~0.4ug/ml; roxithromycin is mainly distributed in body fluids and tissues, with high and durable tissue concentration and cell concentration. Moreover, it has a half-life of up to 12 h while the value for erythromycin is only 1.5~2.0h. 4, in clinical medicine, it is the first-choice drug for the treatment of drug-resistance Staphylococcus aureus and hemolytic streptococcus. In veterinary clinical practice, it is used for the treatment of penicillin-resistant staphylococcus aureus caused severe infection, pneumonia, uterine inflammation and poultry chronic respiratory disease. 5, the goods are mainly used for the treatment of livestock and poultry chronic respiratory disease with good efficacy in the treatment of livestock and poultry staphylococcus and streptococcal disease, chlamydia, spirocheal disease (swine dysentery), infectious pleurisy and rhinitis. 6, indications: avian neck swelling, local heat, pain, difficulty breathing, mouth and nose flow white foam, mucous membranes and skin cyanosis and other symptoms.
Description
Roxithromycin, an oxime ether derivative of erythromycin, is a new macrolide antibiotic of high potency and long duration. Its in v i m activity spectrum is similar to that of erythromycin, but is superior to the latter against Legionella, Mycoplasma and Chlamydia.